The dual PPARα/γ activation by saroglitazar is likely responsible for the attenuation of hepatic fibrosis by promoting fatty acid oxidation, reducing hepatocellular inflammation, and decreasing hepatic lipid deposition. Here, PPARA is linked to Hepatic fibrosis.